ASYLIA DIAGNOSTICS Asylia Diagnostics is strongly committed to immunotherapy, by detecting ‘hyperprogression’ in cancer patients who are receiving immunotherapy and suffering from rapid growth of the cancer. “ We participated in the call from the BlueHealth Innovation Fund to expand our network. They put us in contact with UZA to do clinical research. “ Andrey Khmelevskiy CEO & founder Asylia Diagnostics 25
27 Online Touch Home